Novo Holdings A/S’s Hemab Therapeutics COAG Stock Holding History

Novo Holdings A/S’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154M	Buy	+4,180,550	New	+$115M	8.92%	3

Other funds holding COAG

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Novo Holdings A/S's COAG Position: Q2 2026 in Review

Novo Holdings A/S opened a new position in Hemab Therapeutics (COAG) in Q2 2026: 4,180,550 shares worth $154M. The stake represents 8.92% of the portfolio and ranks #3 among its holdings.

51 funds tracked by Wall St. Rank hold COAG as of Q2 2026.

Novo Holdings A/S held 4,180,550 shares of Hemab Therapeutics worth $154M as of Q2 2026.
Hemab Therapeutics was a new Novo Holdings A/S position in Q2 2026.
Hemab Therapeutics made up 8.92% of Novo Holdings A/S's portfolio in Q2 2026, its #3 holding.
51 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.